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Nitrogen-containing bisphosphonates (N-BP), including zoledronic acid (ZOL) and alendronate (ALD), have been
proposed as sensitisers in γδ T cell immunotherapy in pre-clinical and clinical studies. Therapeutic efﬁcacy of N-
BPs is hampered by their rapid renal excretion and high afﬁnity for bone. Liposomal formulations of N-BP have
been proposed to improve accumulation in solid tumours. Liposomal ALD (L-ALD) has been suggested as a suit-
able alternative to liposomal ZOL (L-ZOL), due to unexpectedmice death experienced in pre-clinical studies with
the latter. Only one study so far has proven the therapeutic efﬁcacy of L-ALD, in combination with γδ T cell im-
munotherapy, after intraperitoneal administration of γδ T cell resulting in delayed growth of ovarian cancer in
mice. This study aims to assess the in vitro efﬁcacy of L-ALD, in combination with γδ T cell immunotherapy, in
a range of cancerous cell lines, using L-ZOL as a comparator. The therapeutic efﬁcacywas tested in a pseudo-met-
astatic lungmousemodel, following intravenous injection of γδ T cell, L-ALD or the combination. In vivo biocom-
patibility and organbiodistribution studies of L-N-BPswere undertaken simultaneously.Higher concentrations of
L-ALD (40–60 μM) than L-ZOL (3–10 μM) were required to produce a comparative reduction in cell viability in
vitro,whenused in combinationwith γδ T cells. Signiﬁcant inhibition of tumour growthwas observed after treat-
ment with both L-ALD and γδ T cells in pseudo-metastatic lung melanoma tumour-bearing mice after tail vein
injection of both treatments, suggesting that therapeutically relevant concentrations of L-ALD and γδ T cell
could be achieved in the tumour sites, resulting in signiﬁcant delay in tumour growth.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
Circulating gammadelta (γδ) T cells represent 1–10%of all peripher-
al blood T lymphocytes [1] and predominantly express the Vγ9Vδ2 T
cell receptor (TCR) [2]. They recognize non-peptide phosphoantigens
(PAgs) such as isopentyl pyrophosphate (IPP) [3]. In human cells,
PAgs are generated via the mevalonate pathway, which is generally up-
regulated in transformed cells [4]. Vγ9Vδ2 T cells play an important role
in cancer immunosurveillance [5] and have been used clinically in adop-
tive immunotherapy of cancer [6–11]. Sensitisation approaches in im-
munotherapy have been sought to improve therapeutic outcomes.
Nitrogen-containing bisphosphonates (N-BPs), such as zoledronic acid
(ZOL) or alendronate (ALD), are known to inhibit farnesyl pyrophos-
phate (FPP) synthase, an enzyme in the mevalonate pathway, in cancer
cells, causing intracellular accumulation of PAgs [12]. Exposure of
Vγ9Vδ2 T cells to PAgs results in their activation via release of pre-
formed perforin, granzymes and cytokines, and can lead to direct elim-
ination of tumour cells [13].
It has been shown that pre-treatment of tumour cells with low con-
centrations of N-BPs, can sensitise them to killing by Vγ9Vδ2 T cells,
resulting in an overall additive or synergistic cytotoxicity in vitro [14–
18], in vivo [19–26] and in clinical studies [8,9,27]. Therapeutic efﬁcacy
of N-BPs is hampered by their rapid renal excretion and high afﬁnity
for bone [28]. Improved pharmacokinetic proﬁle and enhanced passive
accumulation and retention within solid tumours has been achieved by
encapsulation of ZOL and ALD into liposomes (L-ZOL and L-ALD) [29,
30]. L-ZOL was able to sensitise a number of ovarian cancer cell lines
to destruction by Vγ9Vδ2 T cells in vitro [23]. However, its use in vivo
was prohibited by the profound toxicity and sudden mice death [23,
29]. Several studies have reported the use of L-ALD for therapeutic ap-
plications in cancer [31] and inﬂammatory conditions [32–35] pre-clin-
ically. L-ALD has been shown to be effective when used with Vγ9Vδ2 T
cells in an ovarian cancer model in vivo [23]. A clinical study is due to
commence to evaluate the use of L-ALD in preventing coronary artery
restenosis [36].
Journal of Controlled Release 241 (2016) 229–241
⁎ Corresponding authors.
E-mail addresses: john.maher@kcl.ac.uk (J. Maher), khuloud.al-jamal@kcl.ac.uk
(K.T. Al-Jamal).
http://dx.doi.org/10.1016/j.jconrel.2016.09.023
0168-3659/© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Contents lists available at ScienceDirect
Journal of Controlled Release
j ourna l homepage: www.e lsev ie r .com/ locate / jconre l
While several studies have reported the use of L-ALD or L-ZOL as a
monotherapy in cancer models [31,37–39], only one previous study
has explored L-ALD in combination with γδ T cells in tumour mouse
model, following local (IP) administration of γδ T cells to treat ovarian
tumours [23]. In this studywe hypothesise that systemic administration
of γδ T cells is able to result in signiﬁcant tumour growth delay when
combined with L-ALD therapy in a pseudo-metastatic lung melanoma
model. Additionally, the in vivo toxicity and biodistribution of L-ZOL
and L-ALD has not been directly compared before. The aim of this
study is to evaluate the in vitro potency, in vitro and in vivo efﬁcacy of li-
posomal alendronate in combination with γδ T cell immunotherapy in
cancerous cell lines and mice, respectively. In addition to efﬁcacy stud-
ies, whole body organ biodistribution and in vivo toxicity were per-
formed, bringing this formulation a step further towards
biopharmaceutical development and evaluation in pre-clinical models.
2. Materials and methods
2.1. Materials
1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-
dipalmitoyl 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (ammonium salt) (DSPE-
PEG2000) were obtained from Lipoid (Germany). 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-diethylenetriaminepentaacetic
acid (ammonium salt) (DSPE-DTPA) was purchased from Avanti Polar
Lipids, Inc. (USA). Dextrose, cholesterol, sodium chloride, phosphate
buffered saline (PBS) tablet, N-(2-Hydroxyethyl)piperazine-N′-(2-
ethanesulfonic acid) (HEPES), methanol (analytical reagent grade),
chloroform (analytical reagent grade), isopentane (analytical reagent
grade), diethyl ether (analytical reagent grade) and Sephadex G75
were purchased from Sigma (UK). Zoledronic acid was a kind gift from
Novartis (Switzerland). PD-10 desalting column was obtained from GE
Healthcare Life Sciences (UK). Snake Skin® dialysis tubing (MWCO
10000 Da) was purchased from Thermo-ﬁsher (USA). Dulbecco's mod-
iﬁed Eagle's medium (DMEM), Glutamax™ and antibiotic-antimycotic
solution were purchased from Invitrogen (UK). Foetal Bovine Serum
(FBS) was purchased from First Link (UK). Thiazolyl blue tetrazolium
bromide (MTT) and alendronate sodium trihydrate, were obtained
from Alfa Aesar (UK). DMSO was obtained from Fisher (UK). Human
IFN-γ ELISA Ready-set-go kit was purchased from eBiosciences (UK).
Mouse TNF (Mono/Mono) ELISA setwas purchased fromBDBiosciences
(USA). Indium-111 chloride was obtained fromMallinckrodt (NL). Thin
layer chromatography (TLC) strips for radio-labelling were purchased
from Agilent Technologies UK Ltd. (UK). Isoﬂurane (IsoFlo®) for anaes-
thesia was purchased from Abbott Laboratories Ltd. (UK). All reagents
were used without further puriﬁcation.
2.2. Preparation of liposomes
Liposomeswere prepared using the thin ﬁlm hydration (TFH)meth-
od. DSPC, cholesterol and DSPE-PEG2000 (55:40:5 mole ratio) were
added to a 25 ml round-bottom ﬂask and 2 ml chloroform/methanol
(4:1 v/v) was added. A thin lipid ﬁlm was formed upon removal of the
solvent under reduced pressure using a rotary evaporator (Rotavapor®
R-210, Buchi UK). The lipid ﬁlm was ﬂushed with nitrogen to remove
any remaining traces of organic solvent. The lipid ﬁlmwas then hydrat-
ed with 1 ml of PBS, adjusted to pH 7.4. The liposome suspension was
left for 1 h at 60 °C and was vortexed (Vortex genie 2, Scientiﬁc Indus-
tries Inc., USA) every 15 min [40]. The resulting suspension was stored
at 4 °C. The size and polydispersity (PDI) of the liposomeswere reduced
with serial extrusion steps. The liposome suspension was extruded
using themini-extruder (Avanti Polar Lipids, USA) through polycarbon-
ate membranes (Avanti Polar Lipids, USA) with pore sizes 0.8 μm (5×),
0.2 μm (5×), 0.1 μm (10×) and 0.08 μm (15×), above the phase transi-
tion temperature for the lipid. When formulating L-ZOL and L-ALD, the
lipid ﬁlms were hydrated with either 100 mM ZOL or 100 mM ALD in
HEPES Buffered Saline (HBS; 20 mM HEPES and 150 mM NaCl,
pH 7.4), and free ZOL and ALD was removed by dialysis against HBS
using a 10,000 Da MWCO dialysis bag. Liposomes were prepared at a
ﬁnal lipid concentration of 25 mM.
2.3. Cancer cell line culture conditions
The cell lines PANC-1 (CRL-1469™), PANC0403 (CRL-2555™) were
obtained from ATCC®. A375Ppuro and A375Pβ6 cell lines were created
using the human melanoma cell line A375P (CRL-3224™), which was
infected with pBabe retroviruses encoding puromycin resistance alone
(A375Ppuro) or in combination with cDNA for human β6 integrin
(A375Pβ6), as previously reported [41]. The A375Ppuro and A375Pβ6
were a kind gift from Dr. John Marshall (QMUL). All cell lines were
maintained at 37 °C, 5% CO2 and 5% relative humidity. Advanced RPMI
or DMEM media were used, both of these were supplemented with
10% FBS, 1% Glutamax and 1% Penicillin/Streptomycin.
2.4. Treatment of cancer cell lines with N-BPs in monotherapy studies
The cell lines A375Ppuro and PANC-1were seeded in a 96-well plate
at a seeding density of 10,000 cells/well. Cells were treated with 0.01–
100 μM ZOL or ALD, 20–200 μM empty liposomes (EL) or were left un-
treated. After 24, 48 or 72 h incubation, the cell viability was assessed
with MTT, as described below.
2.5. Treatment of cancer cell lines with N-BPs/liposomal N-BPs and γδ T
cells in combination therapy studies
The cell lines A375Ppuro, A375Pβ6, PANC-1 and PANC0403 were
seeded at 50,000 cells/well in a 96-well plate. Conﬂuent monolayers of
each cancer cell line were treated for 24 h with ZOL, ALD, L-ZOL or L-
ALD at concentrations of 3–10 μM (ZOL and L-ZOL), 40–60 μM (ALD
and L-ALD) or were left untreated. With regards to L-ZOL and L-ALD,
the concentrations used indicate the amount of encapsulated ZOL and
ALD after puriﬁcation. As a control, cells were also treated with EL at
concentrations of 36.5–219 μM After 24 h, the treatments were re-
moved and the monolayers were then co-cultured with 2.5 × 105 ex
vivo expanded γδ T cells (or γδ T cell culture media as a control) per
well for a further 24 h. Cell viability was assessedwithMTT as described
below.
2.6. MTT assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) solution was prepared in PBS at a concentration of 5 mg/ml and
was diluted in media (1:6 v/v) prior to use. The supernatant of each
well was removed and MTT solution (120 μl) was added to each well.
The plates were then incubated at 37 °C and 5% relative humidity for
3 h. The MTT solution from each well was removed and DMSO was
added to solubilise (200 μl/well for 96 well) the crystals formed and
this was incubated for 5 min at 37 °C, to eliminate entrapped air bub-
bles. The absorbance was read at 570 nm with subtraction readings at
630 nm to normalise for cell debris (FLUOStar Omega, BMG Lab Tech).
Percentage cell viability (%) was calculated as a percentage of untreated
cells (equation in SI). Cell viability was expressed as mean ± standard
deviation (n= 5).
2.7. Determination of IFN-γ concentration with ELISA
Supernatant from the co-culture assay was removed from each of
the wells immediately before the cytotoxicity assay was performed.
The supernatant was centrifuged to remove the γδ T cells and was
stored at −80 °C until required. Supernatants were diluted 1:40 and
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analysed using a human IFN-γ ELISA Ready-set-go-kit as per the
manufacturer's protocol.
2.8. Radiolabelling of liposomes
DSPC: cholesterol: DSPE-PEG2000:DSPE-DTPA (54:40:5:1mole ratio)
liposomes were prepared with the TFH method, as described above,
then radiolabelled with 111In [42]. Brieﬂy, the required volume of
111In, containing 1 MBq or 10–15 MBq per mouse for gamma counting
or SPECT/CT imaging studies, respectively, was added to 2 M ammoni-
um acetate buffer (one-ninth of the reaction volume, pH 5.5). This
was then added to the liposome sample (100 μl of 20 mM liposomes/
mouse) to give a ﬁnal ammonium acetate concentration of 0.2 M. The
mixture was incubated for 30 min at room temperature with vortexing
every 10min. The reactionwas quenched by the addition of 0.1M EDTA
solution to the mixture (5% v/v of the reaction mixture) to chelate free
111In. Unbound 111In:EDTA was removed using NAP-5 desalting col-
umns equilibrated with PBS with the liposomes collected in fractions
1–3 (~150 μl per injection dose).
2.9. Efﬁciency and stability of the radiolabelling in serum
Samples of the radiolabelled liposomes or 111In:EDTA were spotted
in glass microﬁbre chromatography paper impregnated with silica gel.
These strips were then developed using a mobile phase of 50 mM
EDTA in 0.1 M ammonium acetate. Strips were placed on a multi-pur-
pose storage phosphor screen (Cyclone ®, Packard, Japan) and kept in
an autoradiography cassette (Kodak Biomax Cassette ®) for 10 min.
Quantitative autoradiography countingwas then carried out using a cy-
clone phosphor detector (Packard ®, Australia). The labelling stability
was tested by incubation of the radio-conjugates in the presence or ab-
sence of foetal bovine serum (FBS). Samples were diluted in 50% FBS or
PBS [1:2 (v/v)], and incubated for 24 h at 37 °C. The percentage of 111In
(immobile spot) still conjugated to the liposomeswas evaluated by TLC,
using the same protocol, as described above.
2.10. Animal models
All animal experiments were performed under the authority of pro-
ject and personal licences granted by the UK Home Ofﬁce and the
UKCCCR Guidelines (1998). Male NOD SCID gamma (NSG) mice (~
20 g), 4–6 weeks old, were obtained from Charles River (UK). Subcuta-
neous (s.c.) tumours were established by injecting 5 × 106 cells
A375Pβ6 in 100 μl PBS into each of the rear-ﬂanks of the mouse. The
size of the tumour was measured using callipers and tumour area and
volume could thenbedeterminedusing the equation Tumour volume=
width*width*length*(3.14/6). Experiments were performed when tu-
mours reached ~300 mm3.
2.11. In vivo toxicity studies of L-ALD and L-ZOL in NSG mice after a single
injection
Non-tumour bearing NSG mice were intravenously injected with
0.1 μmol L-ZOL or 0.5 μmol L-ALD. After 72 h, the mice were sacriﬁced
and the toxicity of L-ZOL and L-ALD assessed using the methods below.
2.11.1. Spleen weight
The spleenswere excised from eachmouse andweighed using a lab-
oratory balance (GeniusME, Sartorius, Germany).
2.11.2. Haematological proﬁle
Whole blood samples were obtained via cardiopuncture using
K2EDTA as an anti-coagulant. Fresh blood smears were made using
5 μl blood and the haematological proﬁles of these samples were per-
formed by the Royal Veterinary College (London, UK).
2.11.3. Serum biochemistry
Serumwas obtained from some of whole blood samples by allowing
the blood to clot and centrifuging at for 15min at 1500 g. The serumbio-
chemistry proﬁles were performed by the Royal Veterinary College
(London, UK).
2.11.4. TNF-α serum levels
TNF-α ELISAwas performed on serum samples (diluted 1:3) using a
mouse TNF-α (Mono/Mono) ELISA set as per the manufacturer's
protocol.
2.11.5. Organ histology
Organs were immediately ﬁxed in 10% neutral buffer formalin as 5
mm2 pieces. These pieces were then parafﬁn-embedded and sectioned
for haematoxylin and eosin stains (H&E) according to standard histo-
logical protocols at the Royal Veterinary College. The stained sections
were analysed with a Leica DM 1000 LED Microscope (Leica
Microsystems, UK) coupled with CDD digital camera (Qimaging, UK).
2.11.6. Survival
Mice were injected with 0.1 μmol L-ZOL (n= 2) or 0.5 μmol L-ALD
(n= 10) and observed for weight loss and overall appearance daily.
2.12. In vivo toxicity of L-ALD in NSG mice after multiple injections
Non-tumour bearing NSG mice were injected with at one week in-
tervals with 0.5 μmol L-ALD for a total of three doses. The blood,
serum and organs of the mice were analysed as above, with the mice
sacriﬁced 72 h after the ﬁnal injection.
2.13. Whole body SPECT/CT imaging of radiolabelled liposomes in
A375Pβ6-tumour bearing mice
Each mouse was injected with radiolabelled liposomes at 2 μmol
each, containing 1 MBq or 10–15 MBq, for biodistribution and SPECT/
CT studies, respectively, via tail vein injection. Mice were imaged with
nanoSPECT/CT scanner (Bioscan®,USA) at different timepoints; imme-
diately after the i.v. administration (0–30 min), 4 h and 24 h. For each
mouse, a tomography was initially done (45 Kvp; 1000 ms) to obtain
parameters required for the SPECT and CT scanner, including the
starting line, ﬁnish line and axis of rotation of the acquisition. SPECT
scans were obtained using a 4-head scanner with 1.4 mm pinhole colli-
mators using the following settings: number of projections: 24; time
per projection: 60 s and duration of the scan 60 min. CT scans were ob-
tained at the end of each SPECT acquisition using 45 Kvp. All data were
reconstructedwithMEDISO (medical Imaging System) and the combin-
ing of the SPECT and CT acquisitions were performed using PMOD®
software.
2.14. Gamma scintigraphy of radiolabelled liposomes in A375Pβ6-tumour
bearing mice
After 24 h, mice were sacriﬁced and the major organs (brain, lung,
liver, spleen, kidney, heart, stomach and intestine), muscle, skin, bone
(femur), carcass and tumours were collected, weighed and placed in
scintillation vials. Additionally, 5 μl blood sampleswere collected at var-
ious time points (5, 10, 30, 60, 240 and 1440 min). Each sample was
analysed for [111In] speciﬁc activity using an automated gamma counter
(LKBWallac 1282 Compugamma, PerkinElmer, UK) together with dilu-
tions of injected dose with dead time limit below 60%. The gamma rays
emitted by the radioisotope were detected, quantiﬁed and corrected for
physical radioisotope decay by the gamma counter. Radioactivity read-
ings (counts per minute- CPM) were plotted as percentage of injected
dose per organ (%ID/organ) or percentage of injected dose per gram of
tissue (%ID/g). The data were expressed as the mean of triplicate sam-
ples ± SD.
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2.15. Therapy study
Male NSG mice (4–6 weeks) were inoculated with 5 × 106
A375Pβ6.luc by i.v injection to form experimental metastatic lung tu-
mours. Bioluminescence imaging of mice was carried out on Day 6 as
described above and mice were divided into 4 treatment groups:
naïve, L-ALD,γδ T cells and L-ALD and γδ T cells combination treatment.
Doses used in therapy experiments were 0.5 μmol of ALD/mouse (L-
ALD) and 1 × 107 cells/mouse (γδ T cells), all injected via the tail vein.
Three doses of each treatment were given at one week intervals on
days 7, 14 and 21. In the case of the combination treatment, mice
were pre-injected with L-ALD (days 6, 13, and 20) then injected with
γδ T cells (days 7, 14, and 21). Tumour growth wasmonitored by biolu-
minescence imaging twice weekly (days 6, 10, 13, 17, 20, 24, 27), as de-
scribed above.
2.16. Determination of IFN-γ concentration with ELISA
Animals from the therapy study were sacriﬁced and sera was
analysed for human IFN-γ. Sera were diluted 1:2 and analysed using a
human IFN-γ ELISA Ready-set-go-kit as per the manufacturer's
protocol.
2.17. Statistics
For all experiments, datawere presented asmean±SD,where n de-
notes the number of repeats. Independent variable Student t-tests were
performed using IBM SPSS version 20 for in vitro cytotoxicity studies.
For in vivo studies, signiﬁcant differences were examined using one-
way ANOVA. The t-value, degrees of freedom and two-tailed signiﬁ-
cance (p-value) were determined. *p b 0.05, **p b 0.01 and ***p b 0.001.
3. Results
3.1. L-ZOL and L-ALD of comparable size and drug loading were prepared
L-ZOL and L-ALD composed of DSPC:cholesterol:DSPE-PEG2000
(55:40:2 mole ratio) were formulated using the Thin Film Hydration
(TFH)method (Fig. S1), extruded and puriﬁed using dialysis. Liposomes
were also prepared using the reverse phase evaporation (RVE) method
as a comparison, but as liposomes produced by the two methods had
the same characteristics, TFH method was used to produce liposomes
for all subsequent experiments. Liposomes exhibited a hydrodynamic
size of 155.4–159.0 nm, with narrow polydispersity index (PDI of
0.045–0.104) and slightly negative zeta potential (−11.7 to −
14.0 mV) (Table S1). Methods were developed to quantify the amount
of ZOL and ALD encapsulated into liposomes, as described in the supple-
mentary information, using UV–Vis or HPLC (for ZOL quantiﬁcation)
(Fig. S2), copper sulphate-based UV spectroscopy method or o-
phthalaldehyde (OPA)-based ﬂuorescence methods (for ALD quantiﬁ-
cation) (Fig. S3). Our results showed that both ZOL and ALD had similar
encapsulation efﬁciencies (% EE) ranging from5.2–6.4% (Table S2). Drug
loading of 0.23–0.27 mmol ZOL or ALD per mmol lipid was obtained
(p N 0.05).
3.2. In vitro anti-tumour activity of ZOL is more potent than ALD
The cytotoxicity of ZOL and ALD as a monotherapy was assessed
using the melanoma cell line A375Ppuro and the pancreatic cell line
PANC-1. Additionally empty liposomes (EL) were tested as controls.
These results would enable non-toxic ranges of both N-BPs and EL to
be established for use in co-culture studies with γδ T cells. ZOL and
ALD were tested in the range of 0.01–100 μM for 24, 48 and 72 h of in-
cubation. Time- and dose-dependent cytotoxicity was elicited by both
N-BPs. Cell viability results for 24, 48 and 72 h are shown in Figs. S5
and S6. In order to compare the cytotoxicity of the two N-BPs, cell
viability at 72 h was used to calculate the IC50 values for ZOL and ALD
in the two cell lines (Fig. 1). IC50 values of ZOL were 18.86 μM and
55.98 μM for A375Ppuro and PANC-1, respectively. IC50 values of ALD
were 37.92 μM and 106.9 μM for same cell lines. It was concluded that
PANC-1 cells weremore resistant thanA375Ppuro to the direct cytotox-
ic action of N-BPs. Moreover, ZOLwasmore potent that ALD in both cell
lines. ZOL and ALD concentration ranges selected for co-culture studies
with γδ T cells were 3–10 μM and 40–60 μM, respectively. It is worth
mentioning that such high IC50 values for both drugs suggests that nei-
ther is suitable for use as an anti-cancer agent for non-osseous tumours.
In case of EL, a reduction in cell viability of PANC-1 was observed at
concentrations N200 μMwith cell viabilities of 87.0 ± 1.5% and 87.9 ±
8.8% after 48 and 72 h, respectively (Fig. S7). A375Ppuro cells proved
more sensitive to non-speciﬁc toxic effects of EL with cell viabilities of
72.5 ± 5.7% and 45.5 ± 3.4% under similar treatment conditions (Fig.
S7). In co-culture studies with γδ T cells, cancer cells will be treated
with liposomal formulations for only 24 h at concentrations b40 μM
(ZOL) and b240 μM (ALD), after which the drug is removed. Cells will
be further incubated for 24 h with γδ T cells. This incubation protocol
is unlikely to result in signiﬁcant non-speciﬁc toxicity from the carrier
itself.
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Fig. 1. IC50 values of N-BPs after 72 h incubation for different human cancer cell lines. The
IC50 values were determined for the melanoma cancer cell line A375Ppuro and the
pancreatic cancer cell line PANC-1 incubated with (A) ZOL or (B) ALD for 72 h. IC 50 are
in the order of PANC-1 N A375Ppuro for both ALD and ZOL. Higher IC50 values were
obtained for ALD than ZOL. R2 values of 0.9988 (ALD PANC-1 and ZOL A375Ppuro).
0.9736 (ALD A375Ppuro) and 0.9718 (ZOL PANC-1) were obtained. Data was expressed
as mean ± SD (n= 5).
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3.3. L-ZOL and L-ALD can sensitise cancer cells to destruction byγδ T cells in
co-culture studies
Free and liposomal N-BPs were then used in combination with γδ T
cells, to assess whether pre-treating the cells with theN-BPswould sen-
sitise cancer cells for destruction by γδ T cells. The isolation and expan-
sion protocol used to generate and characterise Vγ9Vδ2 T cells is
described in supplementary information (Figs. S8 and S9). In this exper-
iment, two melanoma (A375Ppuro and A375Pβ6) and two pancreatic
(PANC-1 and PANC0403) cancer cell lines were used. Each pair of cells
included anαvβ6 integrin positive and negative cell line to allow for fu-
ture use of targeted liposomes. We hypothesise that free and liposomal
N-BPs or γδ T cells are not toxic to cancer cells when used individually
under the conditions tested, but their pre-treatment with N-BPs sensi-
tise them to killing by γδ T cells. A scheme of the treatment protocol is
shown in Fig. S10.
Initial experiments focused on ZOL and L-ZOL. As expected, ZOL, L-
ZOL or γδ T cells exerted no cytotoxic effect against these tumour cells
when used individually, at previously determined sub-toxic concentra-
tions (black bars, Fig. 2). By contrast, a signiﬁcant and dose-dependent
reduction in cell viability was seen when free ZOL or L-ZOL was used
to sensitise tumour cells to subsequent addition of Vγ9Vδ2 T-cells.
This toxic effect was more evident with free ZOL than with L-ZOL
(grey bars, Fig. 2). In keeping with this, PANC0403 cells appeared to
be resistant to L-ZOL/γδ T cells combination therapy, whereas free ZOL
could effectively sensitise these tumour cells.
Next, we evaluated the ability of ALD or L-ALD to sensitise tumour
cells to Vγ9Vδ2 T-cells. In agreement with cell viability studies using
N-BPs as monotherapy, higher concentrations of ALD and L-ALD than
for ZOL, were required to induce reductions in cancer cell viability in
the co-cultures. Cell viabilities of 5–37% and 55–93% were obtained for
ALD and L-ALD, respectively, when used with γδ T cells treatment, at
40–60 μM ALD (grey bars, Fig. 3).
Unlike ZOL and L-ZOL, nodose-dependencywas observed in the case
of ALD or L-ALD treatment, possibly due to the narrower range used
than in the ZOL study. A slight but signiﬁcant reduction in cell viability
was observed when cells were treated with free ALD, in some of the
conditions, despite the absence of γδ T cells (~60–90% % cell viability,
p b 0.05). This is presumably due to the high ALD concentrations used
compared to ZOL. No reduction in cell viability was found when cells
were pre-treated with EL and then γδ T cells, at equivalent concentra-
tions used with the drug (Fig. S11). These studies further conﬁrmed
that the reduction in cancer cell viability is speciﬁc to N-BPs ability to
sensitise cells toγδ T cells. It was also concluded that freeN-BPs can sen-
sitive cancer cells more efﬁciently than their liposomal formulations.
This is not surprising as encapsulation of the drug within liposomes is
likely to slow down its release (Fig. S4), causing a delayed onset of ac-
tion in vitro as has been reported for other drugs [43].
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Fig. 2.Viability of human cancer cell lines after incubationwith γδ T cells and L-ZOL. Cells were treatedwith ZOL or L-ZOL for 24 h at concentrations between 3 and 10 μM. The treatments
were then removed and replaced with 2 × 105 γδ T cells for an additional 24 h, before an MTT assay was performed to determine residual tumour cell viability. The ZOL and L-ZOL were
used at non-toxic concentrations, in the absence of γδ T cells. No background toxicity was found for γδ T cells without N-BP. However, a dose dependent toxicity was found in cells pre-
treated with ZOL or L-ZOL (ZOL N L-ZOL), except for PANC0403. Data was expressed as mean ± SD (n= 5). *p b 0.05, (Student's t-test vs. naive).
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3.4. Interferon (IFN)-γ production is increased proportionally to cell kill
The IFN-γ concentrations in the co-culture supernatants were mea-
sured in order to further conﬁrm that cell kill was speciﬁc toγδ T cell ac-
tivation. In all cases, the use of free N-BPs with γδ T cells led to a
signiﬁcant increase in IFN-γ levels compared to γδ T cells treatment
alone (18–27 vs. ~10 ng/ml) (Fig. 4). Agreeing with the cell viability re-
sults, IFN-γ levels were approximately two-fold higher in cells pre-
treated with free ZOL or ALD than their liposomal formulations (Fig.
4). Only some L-ZOL or L-ALD treatment groups showed signiﬁcant in-
creases in IFN-γ levels, but in a random manner. The good correlation
between cell viability and IFN-γ concentration suggests that cell kill is
due to the activation of γδ T cells.
3.5. In vivo toxicity of L-ZOL and L-ALD following a single injection in NOD
scid gamma (NSG) mice
It has been reported by Shmeeda et al., that L-ZOL resulted in sudden
death of mice (BALB/c and Sabra) when used in vivo [29]. The use of L-
ZOL and L-ALD in NSG mice has not been reported. NSG mice have
been increasingly used for in vivo studies and may have different pro-
ﬁles to other mouse strains, as they are more immunocompromised.
In the work, we used immunocompromised mice, as the aim is to be
able to perform therapy study against human cancers in combination
with human γδ T cells, using these mice. Immuno-competent mice
could not be used to grow human tumours or to inject γδ T cells,
hence were not used. In this study, a direct comparison was conducted
for L-ZOL and L-ALD using the parameters outlined in Shmeeda et al.,
following a single injection. Based on IC50 values obtained in vitro, a 5-
fold higher dose of L-ALD (0.5 μmol ALD/mouse) than L-ZOL (0.1 μmol
ZOL/mouse) was used in vivo. Mice were sacriﬁced 72 h post single i.v.
injection of liposomal N-BPs (L-N-BPs: L-ZOL or L-ALD), since in previ-
ous studies mice death was observed at 5 days L-ZOL post-injection. Pa-
rameters monitored and ﬁndings obtained are detailed below.
3.5.1. Injection of L-ZOL or L-ALD leads to splenomegaly
Spleens of mice injected with L-ZOL weighed signiﬁcantly more
(0.06 ± 0.02 g) than those of control mice (0.03 ± 0.004 g) (p b 0.01)
(Fig. 5A). Additionally, the spleens of mice injected with L-ALD also
displayed signiﬁcant splenomegaly vs. control spleens (0.06 ± 0.01 g,
p b 0.001).
3.5.2. Haematological analysis
It has been suggested that the systemic toxicity of L-ZOL in mice is
haematologically related [29]. Changes in the full blood count proﬁles
have previously been reported for L-ZOL. Additionally, liposomal N-
BPs are known to have macrophage depleting effects. Agreeing with
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Fig. 3. Cell viability of human cancer cell lines after incubation with γδ T cells and L-ALD. Cells were treated with ALD or L-ALD for 24 h at concentrations between 40 and 60 μM. These
agents were then removed and replaced with 2 × 105 γδ T cells for an additional 24 h, before an MTT assay was performed to measure residual tumour cell viability. The ALD and L-ALD
were used at non-toxic concentrations, in the absence of γδ T cells. No background toxicity was found for γδ T cells without N-BP. However, a non-dose dependent toxicity, in the range
tested, was found in cells pre-treated with ALD or L-ALD (ALD N L-ALD). Data was expressed as mean ± SD (n= 5). *p b 0.05, (Student's t-test vs. naive).
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the previously reported results, L-ZOL caused leucocytosis, neutrophilia
and lymphocytopenia (Fig. 5B–D). White blood cells count and % neu-
trophils increased from 0.77 ± 0.15 × 109/L and 66.2 ± 7.9% in control
mice to 3.22± 2.49 × 109/L (p b 0.01) and 92.2± 4.3% (p b 0.001), in L-
ZOL group. Matching proﬁles for L-ZOL and L-ALD were obtained. The
complete haematological proﬁle for L-ZOL and L-ALD is shown in
Table 1.
3.5.3. Serum biochemistry proﬁle
The biochemistry proﬁle of mice injected with L-ZOL or L-ALD was
studied. Mild but non-signiﬁcant hypocalcaemia and elevated Blood
Urea Nitrogen (BUN)were previously reported for L-ZOL [29]. The com-
plete serumbiochemistry proﬁles are shown in Table S3. In our study, L-
ZOL and L-ALD did not display any signiﬁcant differences to each other
or to control mice. L-ZOL (6.78 ± 0.69 mmol/L) however resulted in
small but signiﬁcant reduction in urea compared to the control
(8.42 ± 0.97 mmol/L) (p b 0.05). Additionally, L-ALD (27.60 ± 1.67 g/
L) led to a signiﬁcant reduction in albumin levels compared to control
mice (31.6 ± 1.67 g/L) (p b 0.01).
3.5.4. TNF-α levels are not increased in mice treated with L-ZOL or L-ALD
It has been shown the L-ZOL can cause a moderate non-signiﬁcant
increase in TNF-α levels in vivo [29]. An ELISA was performed on the
serum to determine TNF-α levels. Mice injected with L-ZOL and L-ALD
did not result in detectable levels of TNF-α in serum. As a positive con-
trol, serum from LPS challenged mice were also tested and produced
TNF-α levels of 1.6 ng/ml. This difference may be due to the mice
been sacriﬁced at an earlier timepoint than in the reported study, or
due to the different strain of mouse used.
3.5.5. No histological abnormalities seen in mice post i.v. injection of L-ZOL
or L-ALD
Histological examination of the major organs (heart, lung, liver,
spleen and kidney) with H&E staining showed no obvious histological
changes compared to control animals (Fig. S12), agreeingwith the pub-
lished study on L-ZOL [29].
3.5.6. Mice treated with L-ZOL but not L-ALD experience sudden death
5 days post injection
Death of mice injected with L-ZOL (0.1 μmol ZOL), without warning
sign, has been reported to occur 5–7 days after injection BALB/c and out-
bred Sabra mice [29]. Two NSG mice were injected in this study. Mice
were found dead without showing signs of physical abnormalities or
weight loss. Itwas judged unethical to injectmoremicewith this formu-
lation. On the other hand, allmice injectedwith 0.5 μmol L-ALD (n=10)
showed 100% survival over the entire study duration (24 days).
3.6. Multiple and single dosing of L-ALD show comparable in vivo toxicity
proﬁles in NSG mice
To mimic dosing regimen used in combination N-BP and γδ T cell
immunotherapy studies, multiple dosing of L-ALD, with weekly
0
5
10
15
20
25
30
35
n
g/
 m
l
0
5
10
15
20
25
30
35
n
g/
 m
l
0
5
10
15
20
25
30
35
n
g/
 m
l
0
5
10
15
20
25
30
35
n
g/
 m
l
PANC-1A375Ppuro
PANC0403
A375P 6
+ γδ T cells + γδ T cells
*** ** ** ** **
*** *** *** *** **
* * *** ****
** *** ** * **
***
Fig. 4. IFN-γ production by γδ T cells after incubation with cancer cells. IFN-γ ELISA was performed on supernatant removed from the co-culture experiment, prior to the MTT assay, for
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intervals, was performed. The overall in vivo toxicity was compared to
that of single administration.Micewere sacriﬁced 72 h after the ﬁnal in-
jection. The spleen weights (Fig. 5A), haematology (Fig. 5B–D and Table
S4) and biochemistry (Table S5) proﬁles were not signiﬁcantly different
from values obtainedwith single L-ALD injection. This suggests that the
toxicity from L-ALD was not cumulative.
3.7. In vivo whole body SPECT/CT imaging of EL
The effect that placing N-BPs into liposomes would have on their
biodistribution was then studied. The cell line A375Pβ6 was chosen
due to its favourable in vivo growth and greater ability to be sensitised
to γδ T cells by L-ALD than the other cell lines screened. Liposomes
were formulated to include 1% DSPE-DTPA and were labelled with
111In, which did not affect the physicochemical properties of the lipo-
somes (data not shown). Initial labelling of 86.3% was achieved and in
the presence of PBS or 50% FBS, 87.8 and 91.1% remained bound to the
EL after 24 h, respectively (Fig. S13).Whole body SPECT/CT images of in-
travenously injected [111In]EL in A375Pβ6 subcutaneous tumour-bear-
ing NSG mice were performed in order to track the biodistribution of
EL over time. The mice were imaged at multiple time points up to
24 h post-injection as shown in Fig. S14. At early time-points, EL
displayed high concentrations in the circulation, with activity located
throughout the mouse at 0–30 min and to a slightly lesser extent at
4 h. At 24 h, accumulation of [111In]EL in liver and spleen was observed.
The uptake in A375Pβ6 tumour could not be observed by this imaging
modality, possibly due to prolonged blood circulation of the [111In]EL.
3.8. L-ZOL and L-ALD show similar tumour and organ biodistribution pat-
terns in vivo
The organ biodistribution and tumour uptake proﬁles of [111In]EL,
[111In]L-ZOL and [111In]L-ALD following i.v. injection were assessed
quantitatively by gamma counting in A375Pβ6 subcutaneous tumour-
bearing NSGmice. This was done in order to help understand the toxic-
ity results obtained. Prolonged blood circulation proﬁles were not sig-
niﬁcantly different between the 3 formulations, with 71–81, 52–58
and 15–26%ID remaining in the blood at 1 h, 4 h and 24 h, respectively
(Fig. 6A). Agreeingwith SPECT/CT images, the liver and spleen were the
organs with the highest liposome accumulation (Fig. 6B). Liver uptake
was 23.5 ± 6.5, 25.4 ± 7.2 and 18.7 ± 2.7% ID/g for [111In]EL, [111In]L-
ZOL and [111In]L-ALD, respectively, at 24 h. Spleen uptake was 55.8 ±
13.6, 144.1 ± 70.5 and 148.9 ± 61.1%ID/g for the same formulations.
Both [111In]L-ZOL and [111In]L-ALD showed signiﬁcantly 3-fold higher
spleen uptake than [111In]EL, with no signiﬁcant differences seen be-
tween [111In]L-ZOL and [111In]L-ALD. No signiﬁcant differences in tu-
mour uptake between the three formulations were found (~1.9–3.1%
ID/g) (Fig. 6B, inset). The organ biodistribution proﬁles expressed as %
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Fig. 5. Effects of L-ZOL and L-ALD on blood counts and spleen. NSG mice were injected with 0.1 μmol L-ZOL or 0.5 μmol L-ALD. After 72 h, the mice were sacriﬁced. (A) The spleen was
removed and weighed. A signiﬁcant increase in spleen weight could be seen in the case of both L-ZOL and L-ALD. Blood counts were performed by automatic counting. An increase in
(B) WBC and (C) % Neutrophils was seen when injected with L-ZOL or L-ALD, while a decrease in (D) % Lymphocytes was observed. (Data were expressed as mean ± SD (n= 10 and
n= 5 for spleen weight and blood counts, respectively) *p b 0.05, **p b 0.01, ***p b 0.001. (Student's t-test vs. naive).
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Table 1
Haematological resultsa from male non-tumour bearing NSG mice treated with a single dose of 0.1 μmol L-ZOL or 0.5 μmol L-ALD and sampled 72 h after dosingb.
Controlc L-ZOLc L-ALDc
Mean ± SD Range Mean ± SD Range Mean ± SD Range
WBC 0.8 ± 0.2 0.6–1.0 3.2 ± 2.5⁎⁎ 1.3–3.2 2.2 ± 0.5⁎⁎⁎ 1.7–2.8
Neutrophils 0.5 ± 0.1 0.4–0.7 3.0 ± 2.5⁎⁎ 1.3–2.8 2.0 ± 0.5⁎⁎⁎ 1.5–2.6
Neutrophils % 66.2 ± 7.9 66.0–76.0 92.2 ± 4.3⁎⁎⁎ 87.0–97.0 88.6 ± 3.7⁎⁎⁎ 83.0–91.0
Lymphocytes 0.2 ± 0.1 0.1–0.2 0.1 ± 0.1 0.0–0.2 0.1 ± 0.1 0.0–0.2
Lymphocytes % 21.0 ± 10.4 10.0–22.0 3.0 ± 1.7⁎⁎ 2.0–6.0 5.2 ± 2.2⁎ 2.0–8.0
Monocytes 0.1 ± 0.1 0.0–0.2 0.1 ± 0.1 0.0–0.1 0.1 ± 0.1 0.1–0.2
Monocytes % 10.6 ± 7.9 3.0–23.0 3.8 ± 3.0 1.0–8.0 6.0 ± 3.4 3.0–11.0
Eosinophils 0.0 ± 0.0 0.0–0.0 0.0 ± 0.0 0.0–0.0 0.0 ± 0.0 0.0–0.0
Eosinophils % 2.2 ± 1.3 0.0–3.0 1.0 ± 1.2 0.0–3.0 0.2 ± 0.4⁎ 0.0–1.0
Basophils 0.0 ± 0.1 0.0–0.1 0.0 ± 0.0 0.0–0.0 0.0 ± 0.0 0.0–0.0
Basophils % 3.7 ± 5.1 0.0–9.8 0.0 ± 000 0 0.0–0.0 0.0 ± 0.0 0.0–0.0
RBC 7.7 ± 0.6 7.1–8.7 8.0 ± 0.4 7.4–8.4 7.9 ± 0.5 7.3–8.4
HGB 13.0 ± 1.2 12.1–14.8 13.5 ± 0.7 12.6–14.3 12.7 ± 0.6 12.0–13.3
HCT 43.0 ± 4.3 38.2–49.1 44.2 ± 1.6 42.2–45.6 42.0 ± 2.4 38.8–44.3
MCV 56.1 ± 1.9 53.4–58.7 55.3 ± 1.5 53.6–57.6 52.9 ± 0.5⁎⁎ 52.6–53.7
MCH 17.0 ± 0.4 16.2–17.3 16.9 ± 0.4 16.4–17.5 16.0 ± 0.3⁎⁎ 15.7–16.3
MCHC 30.2 ± 1.0 29.4–31.7 30.5 ± 0.8 29.4–31.4 30.3 ± 0.4 29.9–30.8
RDW 14.6 ± 0.6 13.7–15.2 14.7 ± 0.4 14.0–15.0 14.6 ± 0.2 14.3–14.7
PLT 1331.0 ± 104.2 1179–144 1223.4 ± 194.2 1023–1501 1472. ± 145.7 1232–1572
PCV 35.4 ± 5.2 34.0–44.0 36.0 ± 2.7 32.0–39.0 35.4 ± 2.1 34.0–39.0
Student's t-test vs. naive.
a Values are means ± SD (n= 5).
b Abbreviations and units: WBC, white blood cell, 10e9/L; Neutrophils, 10e9/L; Lymphocytes, 10e9/L; Monocytes, 10e9/L; Eosinophils, 10e9/L; Basophils, 10e9/L; RBC, red blood cells,
10e12/L; HGB, haemoglobin, g/dL; HCT, haematocrit, %; MCV, mean cell volume, fL; MCH, mean cell haemoglobin, pg; MCHC, mean cell haemoglobin concentration, g/dL; RDW, rec cell
distribution width, %; PLT, platelets, 10e9/L; PCV, packed cell volume, %.
c Data was expressed as means ± SD (n= 5).
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.
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Fig. 6. In vivo biodistribution of radiolabelled EL, L-ALD and L-ZOL in A375Pβ6 tumour bearing NSGmice after single dose administration via tail vein injection. NSGmicewere inoculated
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spleen accumulation than EL. Data are expressed as mean ± SD (n= 3) *p b 0.05, **p b 0.01. (Student's t-test vs. naive).
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ID/organ are displayed in Fig. S15. We believe that any differences in in
vivo toxicity are not likely due to differences in pharmacokinetic pro-
ﬁles, since all liposomes exhibited similar size and surface charge.
3.9. Combinatory L-ALD and γδ T cell immunotherapy
To assess whether the dosing regimen of L-ALD used in the toxicity
studies was sufﬁcient to result in the potentiation of the immunothera-
py, a tumour growth delay experiment was performed in the pseudo-
metastatic lung tumour model, following i.v. administration of both
therapeutic agents. At the start of treatment (day 6), all four groups
(naïve, L-ALD, γδ T cells and L-ALD + γδ T cells) had the same average
tumour size (3.4 × 106 photons). After three treatments at oneweek in-
tervals (day 28), the tumour sizes were 6.9 × 109 ± 1.5 × 109 (naïve),
3.5 × 109 ± 1.6 × 109 (L-ALD), 5.3 × 109 ± 1.0 × 109 (γδ T cells), and
2.1 × 109 ± 8.2 × 108 (L-ALD + γδ T cells) photons (Fig. 7). Although
monotherapy of L-ALD or γδ T cells resulted in some tumour growth
delay, only the combination treatment demonstrated a signiﬁcant re-
duction in tumour growth (p = 0.015) with a ~3-fold decrease in tu-
mour growth.
3.10. IFN-γ detected in sera of mice treated with γδ T cells and L-ALD
In order to determine whether L-ALD had activated of γδ T cells in
vivo, the release of IFN-γ from the γδ T cells was measured. Analysis
of sera samples from mice demonstrated detectable levels of human
IFN-γ in the sera of the combinatory group only (9.2 ± 5.1 pg/ml). In
the case of mice treated with γδ T cells alone, an insufﬁcient amount
of human IFN-γwas released to be detected.
4. Discussion
N-BPs have been shown to effectively sensitise various cancer types
to Vγ9Vδ2 T cells in both preclinical [19,21–26] and clinical studies [44–
47]. Due to the known limitations of the pharmacokinetics of
bisphosphonates [28], encapsulating these agents within liposomes of-
fers an attractive solution to increase delivery of bisphosphonates to
non-osseous tumour sites. ZOL is the most potent of the N-BPs [48,49]
and is the most widely used bisphosphonate in γδ T cell immunothera-
py studies. However, in a study by Shmeeda et al. [29], itwas shown that
while encapsulating ZOL in liposomes increased the amount of ZOL in
tumours in vivo, mice unexpectedly died 5–7 days after treatment
with this formulation. This toxicity was also reported by co-authors of
this work [23]. In this study, an alternative bisphosphonate, ALD, in
the liposomal formulation was used and did not result in mice death
at a therapeutically efﬁcacious dose in an intraperitoneal ovarian tu-
mour model. As we have also shown in a pseudo-metastatic lungmela-
noma tumour model (Fig. 7), signiﬁcant inhibition of tumour growth
was observed when L-ALD was used in combination with γδ T cells. A
liposomal formulation of ZOL that was shown to increase survival
time of prostate tumour-bearing mice with no toxicity observed, has
also been reported [50]. However, this formulation was composed of
Egg PC, DSPE-PEG2000 and cholesterol and had also been exposed to
freeze-drying. When comparing the results of this study to their own,
Shmeeda et al., suggested that the use of use of Egg PC and freeze drying
led to a less stable formulation, and this could be the reason for the dis-
crepancy in toxicity in vivo work [29]. A hybrid nanoparticle-liposome
formulation has also been prepared consisting of a calcium phosphate
core to which ZOL could bind mixed with DOTAP/cholesterol/DSPE-
PEG2000 liposomes [37]. These hybrid particles achieved a signiﬁcant tu-
mour weight inhibition of 45%, and while no in vivo toxicity tests were
performed, no sudden mouse death was observed [38].
L-ALD has also been used in vivo, as a monotherapy for a murine
breast cancer model [31]. However, while some tumour growth inhibi-
tion was observed this did not reach signiﬁcance, similarly to what we
observe in this work. This suggests that ALD does not reach sufﬁcient
concentrations in tumours to be therapeutically efﬁcacious as a mono-
therapy, even when encapsulated in a liposomal formulation. L-ALD
has also been used in the treatment of inﬂammatory conditions [32–
35]. The ability of ALD liposomes to depletemonocytes andmacrophages
has been shown to inhibit restenosis and endometriosis in a rat model
[35]. This anti-inﬂammatory activity of ALD liposomes has shown to be
effective in the inhibition of restenosis in rabbits in vivo [30]. These lipo-
somes were negatively charged due to the inclusion of distearoyl-
phosphatidylglycerol (DSPG), and had a zeta potential of approximately
−29 mV. Additionally, a clinical trial involving the use of L-ALD in coro-
nary artery restenosis prevention is due to commence this year [36]. ALD
has also been co-encapsulated with doxorubicin (DOX) into liposomes
[39]. Liposomes encapsulating both drugs were shown to be more effec-
tive than liposomes encapsulating DOX alone at inhibiting tumour
growth in 4T1 breast cancer and M109R lung cancer models in BALB/c
mice in vivo. While γδ T cells were not used in this study, the in vivo tox-
icity of L-ALD was also examined with the incorporation of ALD in lipo-
somes shown to lead to a 40 fold increase in IL-1β secretion from
monocytes in vitro, but did not activate the complement system in
human plasma [39]. Although L-ALD has been assumed to be safe substi-
tute for L-ZOL, comparative in vivo toxicity studies have not been per-
formed. In the current report, we examine the ability of L-ALD to
substitute L-ZOL, as a γδ T cells sensitiser in vitro, followed by conducting
a comparative in vivo toxicity study for both formulations after single i.v.
injection, at therapeutically relevant doses inmice. In vivo L-ALD toxicity,
following multiple i.v. injections, mimicking the immunotherapy thera-
py protocol, was also assessed. Organ biodistribution studies of empty
and N-BP loaded liposomes were performed in order to help partially
understand ﬁndings of the in vivo comparative toxicity study.
ALD and ZOL are second and third generation N-BPs, respectively
[51]. In our studies we have seen that ZOL is ~5 times more potent as
both a monotherapy and as a sensitising agent for γδ T cell immuno-
therapy. Similar ﬁndings in relation to the potency of the two N-BPs
have been reported in the literature. ZOL had IC50 values of 0.02 ±
0.00 μM for inhibition of FPP synthase in J774 cell homogenates and
0.003 ± 0.000 μM for inhibition of recombinant human FPP synthase.
ALD, however had IC50 values of 0.50 ± 0.15 μM and 0.05 ± 0.001 μM,
respectively. The necessity to use increased concentrations of L-ALD
compared to L-ZOL is consistent with these ﬁndings. A study that com-
pared four different formulations of L-ZOL on their cytotoxic ability
found that unless the liposomes were targeted to the folate receptor, a
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Fig. 7. In vivo tumour therapy study. Pseudo-metastatic lung A375Pβ6 tumour bearing
mice were treated with L-ALD (0.5 μmol ALD/mouse), 1 × 107 γδ T cells/mouse or both,
intravenously. Three treatments were given intravenously at one week intervals,
commencing on day 6 post-tumour inoculation. Tumour progression was monitored by
bioluminescence imaging. A signiﬁcant reduction in tumour growth was observed for
the combinatory immunotherapy. Data was expressed as mean ± SEM (n = 7).
*p b 0.05, (Student's t-test vs. naïve).
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reduction in cell viability was not observed at concentrations up to
200 μM [52]. However, this study was looking at the direct cytotoxic ac-
tion of ZOL as amonotherapy. Much lower concentrations of ZOL are re-
quired to sensitise cancer cells to γδ T cells hence in our study we did
not explore the active targeting approach and much lower concentra-
tions of ZOL were used. L-ALD however seems to exhibit higher IC50
values than L-ZOL so utilisation of active targeting approach for this
type of formulation in the future is worth investigating, to establish if
lower L-ALD doses, which are more relevant for in vivo settings, can be
used. Co-authors of this work have previously studied the ability of L-
ZOL and L-ALD to sensitise the ovarian cancer cell line IGROV-1 to de-
struction by γδ T cells in vitro [23]. L-ZOL (0.1 μg/ml, ~0.25 μM) and L-
ALD (0.2 μg/ml, ~0.6 μM) led to ~25% apoptotic cells and ~30% reduction
in cell viabilitywhen used in combinationwith γδ T cells, atmuch lower
concentrations than used in our study (3–10 μM and 40–60 μM for L-
ZOL and L-ALD, respectively). These are much lower concentrations
than used in our study (3–10 μMand 40–60 μM for L-ZOL and L-ALD, re-
spectively) but cell lines used are also different.
In the present study, and for the ﬁrst time, we directly compared the
in vivo toxicity of L-ZOL and L-ALD. Based on the results of the in vitro as-
says, L-ALD were used at a concentration ﬁve times higher (0.5 μmol/
mouse) than that of L-ZOL (0.1 μmol/mouse). The dose of L-ALD used
matches that used in the study by Parente-Pereira et al. [23]. Shmeeda
et al. assessed the toxicity of L-ZOL in BALB/c and Sabra mice [29], and
it was shown that L-ZOL resulted in splenomegaly (~200 mg vs. 120
mg/spleen) and leucocytosis (~30 × 103 WBC/μl vs. ~5 × 103 WBC/μl).
Despite the different stain of mice used in this study, similar increases
in spleenweight (0.06± 0.02 g vs. 0.03± 0.004 g) andWBC concentra-
tion (3.22 ± 2.49 10e9/L vs. 0.77 ± 0.15 10e9/L) were observed (Fig. 7).
Macrophage depletion, as a result of liposomal BPs administration, has
been reported to lead to splenomegaly [53]. Additionally there were
several differences between the result reported here and the results of
Shmeeda et al., with no reduction in platelet number or haemoglobin
observed in our study unlike their previous report [29]. Different time
points at which the mice were sacriﬁced post-injection were used
(3 days vs. 5 days, respectively). Consistent to what we report here,
the toxicity of L-ALD has been shown to be non-cumulative after multi-
ple injections by Gabizon and co-workers [39]. Despite the comparable
in vivo toxicity proﬁles of L-ALD and L-ZOL, L-ALD and L-ZOL resulted in
100% and 0%mice survival, respectively, at the studied doses. NSGmice
are not the bestmodels to carryout toxicity studies for two reasons; they
are known to have several defects in cytokine signalling pathways [54].
Secondly, it was previously hypothesised that the mechanism of in vivo
L-ZOL toxicity is linked to cytokine release from macrophages [29]. It is
therefore interesting to observe comparable L-ZOL toxicity proﬁles in
both immunocompetent and immunocompromised mice. Such puz-
zling results cannot be explained using the results presented here. A
previous study by Parente-Pereira et al. [23] used the same dosage reg-
imen of L-ALD and showed no mice death. However, no toxicity proﬁl-
ing was carried out in that study. Different markers for in vivo toxicity
may need to be assessed in order to be able to differentiate between
the toxicity of L-ZOL and L-ALD. For example, in rat and rabbit models,
complement and IL-2βmarkers after injection of L-ALD have been stud-
ied in vivo [55]. L-ALD led to increased secretion of IL-2β in both rat and
rabbit, with minor complement activation seen in rat only. However,
the liposomes in these studies were more negatively charged that
those used in our study, whichmay lead to differences in in vivo toxicity.
Similar studies have not been undertaken for L-ZOL.
The formulation of the liposomes can also inﬂuence their in vivo be-
haviour. In this study, the size of the liposomes iswithin the range (100–
200 nm) reported to be extravasated in regions of leaky vasculature as
part of the EPR effect [56] and the low PDI values indicate that the lipo-
somes are homogenous. The L-ZOL and L-ALD obtained have similar
physicochemical characteristics and drug loading, allowing for direct
comparisons to be made between them (Table S1). In order to better
understand the results of the in vivo toxicity studies, the biodistribution
of EL, L-ZOL and L-ALD in tumour bearingmicewas studied. A three-fold
increase in the spleen uptake of both L-ALD and L-ZOL was observed
compared to EL. The increase in spleen uptake of L-ALD in comparison
to liposomal doxorubicin has been previously reported [39]. The spleen
uptake of L-ALD has not been compared to L-ZOL previously and it was
not known whether a difference in spleen uptake of the two formula-
tions could account for the increased toxicity of L-ZOL. Our results con-
ﬁrmed no signiﬁcant differences in spleen uptake between the uptake
of L-ZOL and L-ALD. Such results at least concluded that the sudden
mice death in case of L-ZOLwas not due to this higher uptake in spleen.
The increased spleen uptake may be as a result of the well-reported
macrophage depletion properties of liposomal N-BPs [32,57], whereby
macrophages that uptake L-ZOL or L-ALD undergomacrophage apopto-
sis [58]. This would result in the trafﬁcking of damaged macrophages
containing L-ZOL or L-ALD to the spleen [59], which also explains the
higher levels of radioactivity detected in the spleen than EL (Fig. 6). Fur-
thermore, this may account for the signiﬁcant increase in spleenweight
observed inmice injectedwith L-ZOL or L-ALD (Fig. 5). Interestingly, de-
spite the higher accumulation of L-ZOL or L-ALD in the spleen no histo-
logical changes were observed in the spleen tissues. The biodistribution
of L-ZOL has previously been reported [29], but empty liposomes were
not used as a control in this study. Once again, however, no discernible
differences between L-ZOL and L-ALD were observed that may account
for the differences in toxicity of these two formulations. Liposomal for-
mulations of drugs were originally proposed to reduce systemic toxicity
of drugs. The increased toxicity of ZOLwhen it was encapsulated into li-
posomes contrasts the original purpose of its nanoformulation and
highlights the importance of considering the free drug and its nanofor-
mulation as two separate entities.
In our study, combinatory γδ T cell immunotherapy was shown to
signiﬁcantly reduce tumour growth in a pre-clinical mouse model.
Mice treated with L-ALD and γδ T cell showed a ~3-fold decrease in tu-
mour growth when compared to naïve mice (p N 0.05). L-ALD has not
yet been used in combination with γδ T cells in clinical studies. Only
one study has been done on the use of L-ALD in combination with
human γδ T cells, by co-authors of this work [23]. In the reported
study, Parente et al. used L-ALD in combination with human-derived
γδ T cells to treat an intraperitoneal ovarian cancer model in mice
[23]. Signiﬁcant reductions in tumour growth was observed in mice
injected with both L-ALD and γδ T cells. Our study utilised the same L-
ALD and γδ T cells doses reported by Parente et al., but the route of γδ
T cells administration was different; Parente et al. injected γδ T cells in-
traperitoneally while in our study cells were injected intravenously.
Both studies however concluded that L-ALD was necessary to improve
the potency of γδ T cells immunotherapy.
Clinically, γδ T immunotherapy has been used for the treatment of
renal cell carcinoma [7,8,45], multiple myeloma [6], non-small cell lung
cancer [11,60] and other various solid tumours [9,10], with disease
stabilisation achieved in the majority of these studies. However, N-BPs
were not used in most of these studies, suggesting that the full potential
of γδ T immunotherapy has yet to be explored. While there is a clinical
trial for L-ALD due to commence as a monotherapy [36], its use as a
sensitiser for γδ T immunotherapy in cancer has yet to be assessed in
humans. It is also possible that L-ALDmay also have anti-cancer activities
unrelated toγδ T cell sensitisation. A direct cytotoxic effectmay not have
a signiﬁcant therapeutic effect at the dose used. However, the ability of L-
ALD to lead to monocyte and macrophage depletion has been well re-
ported and has shown beneﬁts in the treatment of restenosis and endo-
metriosis [55,61]. This aspect of L-ALD activity may help contribute to its
anti-cancer properties as high levels of macrophages in the tumour have
been associated with disease progression and treatment resistance [62].
5. Conclusion
While some toxic side effects were seen after injection of L-ALD,
namely increased spleen weight, leucocytosis, neutrophilia and
239N.O. Hodgins et al. / Journal of Controlled Release 241 (2016) 229–241
lymphocytopenia, mice injected with L-ALD had a 100% survival rate
while L-ZOL resulted in mice death. Despite L-ALD being ~5 times less
potent than L-ZOL at sensitising tumour cells to destruction by γδ T
cells in vitro, it is evident from the in vivo therapy study that therapeu-
tically relevant concentrations of L-ALD and γδ T cells could be achieved
in tumour tissues, following systemic administration. L-ALD has been
shown to be efﬁcacious as a sensitiser for γδ T cell immunotherapy,
and the combinatory therapy resulted in activation of γδ T cells and de-
layed tumour growth in an experimental metastatic lungmousemodel.
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